Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
We read with great interest the recent publications in Cancer Cell regarding seroconversion rates following SARS-CoV-2 vaccination among patients with cancer (Addeo et al., 2021; Thakkar et al., 2021). Both studies demonstrated that a lower proportion of patients with hematologic malignancies seroconverted. Additionally, these individuals had lower absolute antibody titers. Similar data have emerged from other studies, some showing even lower seroconversion rates of 50%–60% in patients with hematologic malignancies (Herishanu et al., 2021). Seroconversion to other standard vaccinations is known to be relatively poor in this population, with rates of ~50% or lower in patients with chronic lymphocytic leukemia, for example, especially in those receiving agents such as Bruton’s tyrosine kinase inhibitors (BTKis) or anti-B cell antibody therapies.
Cancer Cell , commentaire en libre accès, 2020